Literature DB >> 23939498

Pharmacologic therapy for acute pain.

Richard D Blondell1, Mohammadreza Azadfard, Angela M Wisniewski.   

Abstract

The approach to patients with acute pain begins by identifying the underlying cause and a disease-specific treatment. The first-line pharmacologic agent for the symptomatic treatment of mild to moderate pain is acetaminophen or a nonsteroidal anti-inflammatory drug (NSAID). The choice between these two medications depends on the type of pain and patient risk factors for NSAID-related adverse effects (e.g., gastrointestinal, renovascular, or cardiovascular effects). Different NSAIDs have similar analgesic effects. However, cyclooxygenase-2 selective NSAIDs (e.g., celecoxib) must be used with caution in patients with cardiovascular risk factors and are more expensive than nonselective NSAIDs. If these first-line agents are not sufficient for mild to moderate pain, medications that target separate pathways simultaneously, such as an acetaminophen/opioid combination, are reasonable choices. Severe acute pain is typically treated with potent opioids. At each step, adjuvant medications directed at the underlying condition can be used. Newer medications with dual actions (e.g., tapentadol) are also an option. There is little evidence that one opioid is superior for pain control, but there are some pharmacologic differences among opioids. Because of the growing misuse and diversion of controlled substances, caution should be used when prescribing opioids, even for short-term treatment. Patients should be advised to properly dispose of unused medications.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23939498

Source DB:  PubMed          Journal:  Am Fam Physician        ISSN: 0002-838X            Impact factor:   3.292


  23 in total

Review 1.  The Clinical Applications of Extended-Release Abuse-Deterrent Opioids.

Authors:  Nalini Vadivelu; Erika Schermer; Gopal Kodumudi; Jack M Berger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

2.  Opioid and non-opioid pain relief after an emergency department acute pain visit.

Authors:  Raoul Daoust; Jean Paquet; Alexis Cournoyer; Éric Piette; Judy Morris; Justine Lessard; Véronique Castonguay; Gilles Lavigne; Vérilibe Huard; Jean-Marc Chauny
Journal:  CJEM       Date:  2021-01-04       Impact factor: 2.410

3.  Predictors of early postoperative pain interference following orthopaedic surgery.

Authors:  Jamie Kator; Ali Aneizi; Vidushan Nadarajah; Patrick M J Sajak; Min Zhan; Mohit N Gilotra; Ngozi M Akabudike; Jonathan D Packer; R Frank Henn
Journal:  J Orthop       Date:  2020-11-13

4.  Effects of opioid/cannabinoid mixtures on impulsivity and memory in rhesus monkeys.

Authors:  Vanessa Minervini; Charles P France
Journal:  Behav Pharmacol       Date:  2020-04       Impact factor: 2.277

5.  Preferences for Analgesic Treatments Are Influenced by Probability of the Occurrence of Adverse Effects and the Time to Reach Maximal Therapeutic Effects.

Authors:  Chia-Shu Lin; Shih-Yun Wu; Long-Ting Wu
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

6.  Patient-reported adherence to coprescribed proton pump inhibitor gastroprotection in osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis patients using nonsteroidal anti-inflammatory drugs.

Authors:  Kenneth Henriksson; Jesper From; Georgios Stratelis
Journal:  Patient Prefer Adherence       Date:  2014-11-18       Impact factor: 2.711

7.  Assessment of rescue opioid use in patients with post-bunionectomy pain treated with diclofenac potassium liquid-filled capsules.

Authors:  Joyce S Willens; Iwona Bucior; Shay Bujanover; Neel Mehta
Journal:  J Pain Res       Date:  2015-02-04       Impact factor: 3.133

8.  Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers.

Authors:  Brian Meshkin; Katrina Lewis; Svetlana Kantorovich; Natasha Anand; Lisa Davila
Journal:  Int J Biomed Sci       Date:  2015-12

9.  Blockade of Serotonin 5-HT2A Receptors Suppresses Behavioral Sensitization and Naloxone-Precipitated Withdrawal Symptoms in Morphine-Treated Mice.

Authors:  Gang Pang; Xian Wu; Xinrong Tao; Ruoying Mao; Xueke Liu; Yong-Mei Zhang; Guangwu Li; Robert W Stackman; Liuyi Dong; Gongliang Zhang
Journal:  Front Pharmacol       Date:  2016-12-26       Impact factor: 5.810

10.  Retrospective pharmacovigilance analysis of nonsteroidal anti-inflammatory drugs-induced chronic kidney disease.

Authors:  Vardhipathi Sravana Swathi; Shrishti Saroha; Jai Prakash; Shashi Bhushan
Journal:  Indian J Pharmacol       Date:  2021 May-Jun       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.